Pharmacokinetics of Ginkgo biloba extracts

Pharmacopsychiatry. 2003 Jun;36 Suppl 1:S32-7. doi: 10.1055/s-2003-40446.

Abstract

EGb 761 (definition see editorial) Ginkgo extract is produced by a validated production process. Its pharmacologically active constituents, flavonol glycosides and terpene lactones, are kept within a narrow range of 22 to 27 % and 5 to 7 %, respectively, by standardisation. The concentration of ginkgolic acids is below 5 ppm. The constant production process also maintains the concentrations of other constituents such as proanthocyanidins, carboxylic acids and non-flavone glycosides at a fairly constant level. In this article, we will summarise the data on the pharmacokinetics of flavonol glycosides and terpene lactones.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Area Under Curve
  • Case-Control Studies
  • Cross-Over Studies
  • Cyclopentanes / pharmacokinetics
  • Diterpenes*
  • Dose-Response Relationship, Drug
  • Female
  • Flavonoids / pharmacokinetics
  • Free Radical Scavengers / pharmacokinetics
  • Furans / pharmacokinetics
  • Ginkgo biloba
  • Ginkgolides
  • Half-Life
  • Humans
  • Lactones / pharmacokinetics
  • Male
  • Middle Aged
  • Plant Extracts / chemistry
  • Plant Extracts / classification
  • Plant Extracts / pharmacokinetics*
  • Plants, Medicinal
  • Rats
  • Structure-Activity Relationship
  • Time Factors

Substances

  • Cyclopentanes
  • Diterpenes
  • Flavonoids
  • Free Radical Scavengers
  • Furans
  • Ginkgolides
  • Lactones
  • Plant Extracts
  • Ginkgo biloba extract
  • ginkgolide B
  • bilobalide